642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II

Mutation-guided finite-duration acalabrutinib plus venetoclax for relapse after first-line finite-duration COVALENT Bruton tyrosine kinase inhibitor plus venetoclax?based combination therapy in patients with chronic lymphocytic leukemia

Development and multicenter evaluation of a novel 12-color flow cytometric antibody panel and dedicated analysis algorithm for fully standardized automated measurable residual disease (MRD) detection in chronic lymphocytic leukemia

Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability

Correlation between real-world (RW) progression-free survival (rwPFS) and overall survival (OS) among patients (Pts) with first-line (1L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) receiving covalent bruton tyrosine kinase inhibitor

Roginolisib IOA 244 an orally bioavailable selective PI3Kd inhibitor in combination with venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia CLL

A decade of progress A comparative analysis of real world survival in chronic lymphocytic leukemia across therapeutic eras

Normal B Cells in MBL follow divergent maturation pathways that correlate with the IGHV mutation status of the pre leukemic clone

Concomitant use of venetoclax 100 mg and ketoconazole a strong CYP3A4 inhibitor is clinically equivalent to venetoclax 400 mg for treating relapsed or refractory chronic lymphocytic leukemia CLL A real world analysis from the brazilian CLL registry

Baseline clinical characteristics of patients with chronic lymphocytic leukemia CLL from 11 Latin American countries A real world registry analysis

Long term outcomes in high risk patients with chronic lymphocytic leukemia treated with targeted therapies in the real world

Elevated circulating activated FOXP3 regulatory T cell subset in patients with advanced chronic lymphocytic leukemia as a marker for severe infections during 1000 days of follow up

Real world RW use of fixed duration FD ibrutinib venetoclax Ibr Ven in patients pts with previously untreated chronic lymphocytic leukemia small lymphocytic lymphoma CLL SLL Pooled analysis of REALITY worldwide WW and REALITY 2 prospective cohort studies

Updated results from a Phase II study of minimal residual disease guided venetoclax obinutuzumab for the initial treatment of fit patients with chronic lymphocytic leukemia

Multilayer profiling of MRD in patients with relapsed refractory CLL treated with venetoclax based regimens in a real world setting

Characterization of IGHV subgroups and their prognostic relevance in CLL

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB 16673 in patients with relapsed refractory Richter transformation Results from the ongoing phase 1 CaDAnCe 101 study

Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia

Zanubrutinib obinutuzumab sonrotoclax in patients with treatment naive chronic lymphocytic leukemia small lymphocytic lymphoma TN CLL SLL Initial results from an ongoing phase 1 1b study BGB 11417 101

Phase 1 2 studies of DZD8586 in CLL SLL patients after COVALENT and non COVALENT BTK inhibitors and BTK degraders – extended follow up report

Upfront continuous BTK inhibitor BTKi versus time limited venetoclax BTKi combinations in CLL across IGHV subgroups Results of an indirect analysis

Zanubrutinib and venetoclax as initial therapy for CLL SLL with obinutuzumab triplet consolidation in patients with detectable minimal residual disease BruVenG

Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia A real world experience

Venetoclax obinutuzumab in frontline and R R CLL Outcomes compared to age and sex matched general population

SF3B1 mutations are associated with shorter time to first treatment in chronic lymphocytic leukemia